Ablation of Complex Fractionated Electrograms With or Without Additional Linear Lesions for Persistent Atrial Fibrillation
NCT ID: NCT02059369
Last Updated: 2017-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2012-08-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ablation STrategies for Repeat PrOcedures in Patients With Atrial Fibrillation Recurrences
NCT04056390
Stepwise Approach Versus Linear Ablation in Patients With Recurrence of Persistent Atrial Fibrillation
NCT01229475
Repeat Ablation Procedure in Patients With Relapse of Atrial Fibrillation
NCT01229306
Does Atrial Fibrillation (AF) Termination Without Additional Ablation Influence Outcome?
NCT01696344
Atrial Fibrillation Registry 2017
NCT05023590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CFAE ablation
Intervention: Complex fractionated atrial electrograms (CFAE) Ablation
PVI+CFAE+DCC
pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists
CFAE + Lines
CFAE Ablation followed by linear lesions (anterior and Roof line)
PVI, CFAE, anterior and roof line, DCC
PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PVI+CFAE+DCC
pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists
PVI, CFAE, anterior and roof line, DCC
PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* After PVI +CFAE ablation, no termination into sinusrhythm or atrial tachycardia
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Deutsches Herzzentrum Muenchen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Deutsches Herzzentrum München
Munich, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GER-EP-013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.